The US Food and Drug Administration has expanded the indication for pembrolizumab to include the use of the targeted immunotherapy agent plus chemotherapy followed by single-agent pembrolizumab in adults with primary advanced or recurrent endometrial cancer.
Among the MMR-deficient patients, median PFS was not reached in the treatment arm and was 6.5 months in the control arm . Among the MMR-proficient patients, the median PFS was 11.1 vs 8.5 months in the study arms, respectively , according to an FDA
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Law Law Latest News, Law Law Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Supreme Court rejects challenge to FDA’s approval of mifepristoneThe court said that the challengers had no right to be in court at all since they could not show they had suffered any actual injury from the FDA rules.
Source: AKpublicnews - 🏆 387. / 55 Read more »
SCOTUS rejects lawsuit over FDA’s approval of the abortion pillIn a unanimous decision, the court ruled the Alliance for Hippocratic Medicine lacked legal standing to challenge the FDA.
Source: verge - 🏆 94. / 67 Read more »
Supreme Court upholds FDA approval of abortion pill mifepristoneThe Supreme Court on Thursday dismissed a case surrounding a challenge to the common abortion drug mifepristone, saying the plaintiffs lacked standing. The ruling means the drug may continue to be prescribed online and shipped by mail, upholding recent regulatory changes made by the Food and Drug Administration.
Source: dcexaminer - 🏆 6. / 94 Read more »